Royal Victoria Eye and Ear Hospital, Dublin, Ireland.
Sligo University Hospital, Sligo, Ireland.
Cornea. 2019 Aug;38(8):955-958. doi: 10.1097/ICO.0000000000001963.
To describe the clinical features, risk factors, and treatment outcomes after supratarsal injection of triamcinolone for vernal keratoconjunctivitis (VKC).
A retrospective review of all patients treated with supratarsal triamcinolone for VKC between February 2002 and May 2017 at the Royal Victoria Eye and Ear Hospital and Our Lady's Children Hospital Crumlin, Dublin, Ireland, was performed.
Twenty-five patients, 46 eyes, and 145 injections were included for analysis. The mean age at first injection was 9.1 ± 5.7 years. Ninety-six percent of the patients were male. A seasonal variation was noted, with 59 injections (41%) of triamcinolone administered for acute and refractive cases of VKC in the summer compared with 35 (24%), 35 (24%), and 16 (11%) in the spring, autumn, and winter months, respectively. The most common presenting complaint was red eye, which was seen in all cases. Hay fever (64%) was the most common associated systemic disease. Each eye required, on average, 3.2 injections (range 1-9 injections), and the mean duration from the onset of symptoms to final treatment was 3.03 years (range 0-7.9 years). The mean presenting and final visual acuities were 0.33 and 0.11 logarithm of the minimum angle of resolution, respectively (P < 0.0001). During our study period, no patient experienced intraocular pressure rise requiring treatment, development of lenticular opacity, or ptosis after supratarsal injection of triamcinolone.
In this case series, supratarsal triamcinolone was used in cases of VKC in which topical medications had failed to control the disease process. All patients reported improvement after treatment. There were no cases of intraocular pressure rise, lenticular opacity, or ptosis development after treatment.
描述春季角结膜炎（VKC）患者接受上睑板下注射曲安奈德的临床特征、危险因素和治疗效果。
回顾性分析 2002 年 2 月至 2017 年 5 月在爱尔兰都柏林皇家维多利亚眼耳医院和奥利里儿童医院 Crumlin 接受上睑板下曲安奈德注射治疗 VKC 的所有患者的资料。
共纳入 25 例（46 只眼）患者，共接受了 145 次注射治疗。初次注射的平均年龄为 9.1 ± 5.7 岁。96%的患者为男性。观察到季节性变化，与春季（分别为 35 只眼[24%]、35 只眼[24%]和 16 只眼[11%]）、秋季（分别为 35 只眼[24%]、35 只眼[24%]和 16 只眼[11%]）和冬季（分别为 35 只眼[24%]、35 只眼[24%]和 16 只眼[11%]）相比，夏季有 59 只眼（41%）因急性和复发性 VKC 接受了曲安奈德注射治疗。最常见的首发症状是眼红，所有患者均有此症状。过敏性鼻炎（64%）是最常见的相关系统性疾病。每只眼平均需接受 3.2 次注射（范围 1-9 次），从症状出现到最终治疗的平均时间为 3.03 年（范围 0-7.9 年）。治疗前的平均最佳矫正视力和最终最佳矫正视力分别为 0.33 和 0.11 对数最小角分辨率（P < 0.0001）。在研究期间，所有患者在上睑板下注射曲安奈德后均未出现眼压升高、晶状体混浊或上睑下垂需要治疗的情况。
在本病例系列研究中，曲安奈德上睑板下注射用于局部药物治疗未能控制疾病进程的 VKC 患者。所有患者治疗后均有改善。治疗后均未出现眼压升高、晶状体混浊或上睑下垂。
